GenVec appoints chief medical officer
Thomas Davis named to the post of chief medical officer at GenVec. Davis was previously the head of the hematologic malignancies portfolio for the Cancer Therapeutics Evaluation Program at the National Cancer Institute. He will oversee clinical development of the company's gene-based product candidates. FDA placed GenVec's oncologic TNFerade on clinical hold last October after Phase II trial data revealed a potential increased risk of blood clots...
You may also be interested in...
Abbott reported almost 28% revenue growth in the fourth quarter led by the exploding demand for COVID-19 tests and continued success of its FreeStyle Libre continuous glucose monitor.
While representing a smaller population, the ACTIVATE-T trial targeted patients seen as having greater unmet need.
As a freshman member on the US House Energy and Commerce Committee, former St. Jude Medical exec Rep. Angie Craig can help shape future health care, cybersecurity bills.